Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys.
Smith EJ, Olson K, Haber LJ, Varghese B, Duramad P, Tustian AD, Oyejide A, Kirshner JR, Canova L, Menon J, Principio J, MacDonald D, Kantrowitz J, Papadopoulos N, Stahl N, Yancopoulos GD, Thurston G, Davis S. Smith EJ, et al. Sci Rep. 2015 Dec 11;5:17943. doi: 10.1038/srep17943. Sci Rep. 2015. PMID: 26659273 Free PMC article.
A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer.
Crawford A, Haber L, Kelly MP, Vazzana K, Canova L, Ram P, Pawashe A, Finney J, Jalal S, Chiu D, Colleton CA, Garnova E, Makonnen S, Hickey C, Krueger P, DelFino F, Potocky T, Kuhnert J, Godin S, Retter MW, Duramad P, MacDonald D, Olson WC, Fairhurst J, Huang T, Martin J, Lin JC, Smith E, Thurston G, Kirshner JR. Crawford A, et al. Among authors: smith e. Sci Transl Med. 2019 Jun 19;11(497):eaau7534. doi: 10.1126/scitranslmed.aau7534. Sci Transl Med. 2019. PMID: 31217340
A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies.
Skokos D, Waite JC, Haber L, Crawford A, Hermann A, Ullman E, Slim R, Godin S, Ajithdoss D, Ye X, Wang B, Wu Q, Ramos I, Pawashe A, Canova L, Vazzana K, Ram P, Herlihy E, Ahmed H, Oswald E, Golubov J, Poon P, Havel L, Chiu D, Lazo M, Provoncha K, Yu K, Kim J, Warsaw JJ, Stokes Oristian N, Siao CJ, Dudgeon D, Huang T, Potocky T, Martin J, MacDonald D, Oyejide A, Rafique A, Poueymirou W, Kirshner JR, Smith E, Olson W, Lin J, Thurston G, Sleeman MA, Murphy AJ, Yancopoulos GD. Skokos D, et al. Among authors: smith e. Sci Transl Med. 2020 Jan 8;12(525):eaaw7888. doi: 10.1126/scitranslmed.aaw7888. Sci Transl Med. 2020. PMID: 31915305
Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy.
Waite JC, Wang B, Haber L, Hermann A, Ullman E, Ye X, Dudgeon D, Slim R, Ajithdoss DK, Godin SJ, Ramos I, Wu Q, Oswald E, Poon P, Golubov J, Grote D, Stella J, Pawashe A, Finney J, Herlihy E, Ahmed H, Kamat V, Dorvilliers A, Navarro E, Xiao J, Kim J, Yang SN, Warsaw J, Lett C, Canova L, Schulenburg T, Foster R, Krueger P, Garnova E, Rafique A, Babb R, Chen G, Stokes Oristian N, Siao CJ, Daly C, Gurer C, Martin J, Macdonald L, MacDonald D, Poueymirou W, Smith E, Lowy I, Thurston G, Olson W, Lin JC, Sleeman MA, Yancopoulos GD, Murphy AJ, Skokos D. Waite JC, et al. Among authors: smith e. Sci Transl Med. 2020 Jun 24;12(549):eaba2325. doi: 10.1126/scitranslmed.aba2325. Sci Transl Med. 2020. PMID: 32581132
A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells.
DiLillo DJ, Olson K, Mohrs K, Meagher TC, Bray K, Sineshchekova O, Startz T, Kuhnert J, Retter MW, Godin S, Sharma P, Delfino F, Lin J, Smith E, Thurston G, Kirshner JR. DiLillo DJ, et al. Among authors: smith e. Blood Adv. 2021 Mar 9;5(5):1291-1304. doi: 10.1182/bloodadvances.2020002736. Blood Adv. 2021. PMID: 33651100 Free PMC article.
Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning.
Haber L, Olson K, Kelly MP, Crawford A, DiLillo DJ, Tavaré R, Ullman E, Mao S, Canova L, Sineshchekova O, Finney J, Pawashe A, Patel S, McKay R, Rizvi S, Damko E, Chiu D, Vazzana K, Ram P, Mohrs K, D'Orvilliers A, Xiao J, Makonnen S, Hickey C, Arnold C, Giurleo J, Chen YP, Thwaites C, Dudgeon D, Bray K, Rafique A, Huang T, Delfino F, Hermann A, Kirshner JR, Retter MW, Babb R, MacDonald D, Chen G, Olson WC, Thurston G, Davis S, Lin JC, Smith E. Haber L, et al. Among authors: smith e. Sci Rep. 2021 Jul 13;11(1):14397. doi: 10.1038/s41598-021-93842-0. Sci Rep. 2021. PMID: 34257348 Free PMC article.
CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models.
Wei J, Montalvo-Ortiz W, Yu L, Krasco A, Olson K, Rizvi S, Fiaschi N, Coetzee S, Wang F, Ullman E, Ahmed HS, Herlihy E, Lee K, Havel L, Potocky T, Ebstein S, Frleta D, Khatri A, Godin S, Hamon S, Brouwer-Visser J, Gorenc T, MacDonald D, Hermann A, Chaudhry A, Sirulnik A, Olson W, Lin J, Thurston G, Lowy I, Murphy AJ, Smith E, Jankovic V, Sleeman MA, Skokos D. Wei J, et al. Among authors: smith e. Sci Transl Med. 2022 Nov 9;14(670):eabn1082. doi: 10.1126/scitranslmed.abn1082. Epub 2022 Nov 9. Sci Transl Med. 2022. PMID: 36350988
12,150 results
You have reached the last available page of results. Please see the User Guide for more information.